Compare Fortinet Inc (FTNT) vs TG Therapeutics Inc (TGTX) Price & Performance

Fortinet (FTNT) trades at $189.10, down slightly (-0.1%) on the day but near its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Fundamentally, the company demonstrates robust revenue growth, expanding from $4.4B in 2022 to $6.8B in 2025, with exceptional profitability margins including an 80.2% gross margin and 28.17% net income margin. Recent news highlights strong AI security demand and raised 2026 guidance.

Fortinet presents a compelling growth story with superior product economics and market share gains, though elevated valuation ratios (P/E 66.82, P/S 18.79) require continued execution. Key risks include competitive pressures and the stock's premium pricing. Analyst consensus shows mixed sentiment with 42% buy ratings but a consensus price target of $158.64 below current levels, suggesting caution despite strong fundamentals.

TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.

The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.